{
    "action": "final",
    "content": "## Most Important Metric and Category\n\nFor adverse event monitoring in clinical trials, the **most critical metric is serious adverse events (SAEs)**, as these drive regulatory reporting requirements, trial continuation decisions, and immediate medical interventions. The most important category for stratifying safety risk is the **body system affected (System Organ Class)**, which tells clinicians and regulators which organ systems are at risk.\n\n## Key Finding: Serious Events Are Rare and Concentrated\n\nAcross 1,191 total adverse events in this trial:\n- **Only 3 events (0.25%) were classified as serious** (AESER='Y')\n- All 3 serious events occurred in the **Nervous System Disorders** category\n- This represents a 3.0% serious event rate within that body system (3 of 101 nervous system events)\n\n## Safety Profile by Body System\n\nThe data reveals a generally mild safety profile with notable variation across organ systems:\n\n**Highest Volume Systems** (most events reported):\n1. **General Disorders** (292 events) — 0 serious, mostly mild (62% mild, 35% moderate)\n2. **Skin Disorders** (276 events) — 0 serious, predominantly mild (60% mild, 38% moderate)\n3. **Nervous System** (101 events) — **3 serious events**, balanced severity distribution\n\n**Severity Concentration**:\n- **Nervous System Disorders** stands out as the only system with serious events, plus the highest proportion of severe events (10% severe vs. 3-4% in other high-volume systems)\n- Three fatal outcomes occurred across the dataset (in General Disorders, Cardiac Disorders, and Psychiatric Disorders), though none were classified as serious events in the AESER field\n\n**Clinical Implication**: While the overall safety profile appears favorable (99.75% non-serious events), the concentration of all serious events in the nervous system warrants focused monitoring of neurological symptoms. The nervous system also shows a higher severity profile (10% severe) compared to the high-volume skin and general disorder categories (2-3% severe).\n\nThis pattern would inform safety monitoring protocols to prioritize neurological assessments and potentially adjust enrollment criteria to exclude patients with pre-existing neurological conditions.",
    "charts": [
        {
            "kind": "hbar",
            "x": "body_system",
            "series": [
                "total_events"
            ],
            "title": "Adverse Events by Body System (Top 15)"
        },
        {
            "kind": "stacked_bar",
            "x": "body_system",
            "series": [
                "mild_events",
                "moderate_events",
                "severe_events"
            ],
            "title": "Severity Distribution by Body System (Top 15)"
        }
    ]
}